Search Results - "Dota"

The DOTA macrocyclic cavity in metallic radiopharmaceuticals: Mythology or reality? by Adriano Duatti

Connect to this object online.

Radionuclide Cisternography with [⁶⁴Cu]Cu-DOTA by Julia Greiser, Sebastian Groeber, Thomas Weisheit, Tobias Niksch, Matthias Schwab, Christian Senft, Christian Kuehnel, Robert Drescher, Martin Freesmeyer

Connect to this object online.

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs by Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille

Connect to this object online.

Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of αMSH peptide by Hua Yang, Feng Gao, Brooke McNeil, Chengcheng Zhang, Zheliang Yuan, Stefan Zeisler, Joel Kumlin, Jutta Zeisler, François Bénard, Caterina Ramogida, Paul Schaffer

Connect to this object online.

Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate by Falguni Basuli, Olga Vasalatiy, Jianfeng Shi, Kelly C. Lane, Freddy E. Escorcia, Rolf E. Swenson

Connect to this object online.

44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations by Katharina A. Domnanich, Cristina Müller, Renata Farkas, Raffaella M. Schmid, Bernard Ponsard, Roger Schibli, Andreas Türler, Nicholas P. van der Meulen

Connect to this object online.

Radioligand Therapy with [¹⁷⁷Lu]Lu-DOTA-TATE or [¹⁷⁷Lu]Lu-DOTA-TATE and [⁹⁰Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade by Adam Daniel Durma, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Beata Dmochowska, Adrianna Mróz, Wawrzyniec Żmudzki, Grzegorz Kamiński

Connect to this object online.

Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application by Aylin Cankaya, Matthias Balzer, Holger Amthauer, Winfried Brenner, Sarah Spreckelmeyer

Connect to this object online.

177Lu-FA-DOTA-PEG-PLGA Nanoparticles Show Antitumor Efficiency in Targeting Ovarian Cancer by Ziming Guo, Yi Du, Jun Zhao, Sha Sha, Jian Wang

Connect to this object online.

Chilean experience using "Theranostics" for treating metastatic neuroendocrine tumors with [177Lu]Lu DOTA-TATE by Horacio Amaral, Rossana Pruzzo, René Fernández, Vasko Kramer, Cristian Soza-Ried, Irene Coudeu

Connect to this object online.

Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab')2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab')2 - implications for a PET theranostic strategy by Anthony Ku, Misaki Kondo, Zhongli Cai, Jalna Meens, Min Rong Li, Laurie Ailles, Raymond M. Reilly

Connect to this object online.

Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid by M. Meckel, R. Bergmann, M. Miederer, F. Roesch

Connect to this object online.

Network Analysis of the Relationship between Personality Traits and Online Behaviour in Adolescents and Young Adults: A Research on Dota 2 Players by O.V. Rubtsova, S.L. Artemenkov, A.S. Panfilova, A.M. Tokarchuk

Connect to this object online.

Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration by Ashleigh Hull, William Hsieh, Artem Borysenko, William Tieu, Dylan Bartholomeusz, Eva Bezak

Connect to this object online.

In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer by Ashleigh Hull, William Hsieh, William Tieu, Dylan Bartholomeusz, Yanrui Li, Eva Bezak

Connect to this object online.

[⁶⁸Ga]Ga-DOTA-TOC: The First FDA-Approved ⁶⁸Ga-Radiopharmaceutical for PET Imaging by Ute Hennrich, Martina Benešová

Connect to this object online.

The development of 177Lu-DOTA-CC-PSMA following a unified "Click Chemistry" protocol of synthesizing metal nuclide-conjugated radiopharmaceuticals by Xiaobei Zheng, Shuai Xue, Zhongqi Zhao, Shuxin Jin, Shuhua He, Lina Jia, Zheng Li, Christian Vanhove, Filip De Vos, Zijun Kuang, Tiantian Wang, Sara Neyt, Lan Zhang, Xiao Li

Connect to this object online.

Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [¹⁵³Sm]Sm-DOTA-TATE by Koen Vermeulen, Michiel Van de Voorde, Charlotte Segers, Amelie Coolkens, Sunay Rodriguez Pérez, Noami Daems, Charlotte Duchemin, Melissa Crabbé, Tomas Opsomer, Clarita Saldarriaga Vargas, Reinhard Heinke, Laura Lambert, Cyril Bernerd, Andrew R. Burgoyne, Thomas Elias Cocolios, Thierry Stora, Maarten Ooms

Connect to this object online.

⁶⁸Ga-DOTA-D-Alanine-BoroPro Radiotracer for Imaging of the Fibroblast Activation Protein in Malignant and Non-Malignant Diseases by Diana Trujillo-Benítez, Myrna Luna-Gutiérrez, José G. Aguirre-De Paz, Pedro Cruz-Nova, Gerardo Bravo-Villegas, Joel E. Vargas-Ahumada, Paola Vallejo-Armenta, Enrique Morales-Avila, Nallely Jiménez-Mancilla, Rigoberto Oros-Pantoja, Clara Santos-Cuevas, Erika Azorín-Vega, Blanca Ocampo-García, Guillermina Ferro-Flores

Connect to this object online.

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators by Euy Sung Moon, Filipe Elvas, Gwendolyn Vliegen, Stef De Lombaerde, Christel Vangestel, Sven De Bruycker, An Bracke, Elisabeth Eppard, Lukas Greifenstein, Benedikt Klasen, Vasko Kramer, Steven Staelens, Ingrid De Meester, Pieter Van der Veken, Frank Rösch

Connect to this object online.